Y Intercept Hong Kong Ltd Purchases New Shares in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Key Points

• Y Intercept Hong Kong Ltd has acquired a new stake in Arcturus Therapeutics Holdings Inc., purchasing 23,077 shares valued at approximately $244,000, representing a 0.09% ownership in the company.
• Institutional investors own about 94.54% of Arcturus Therapeutics' stock, with several hedge funds significantly increasing their positions in recent months.
• Despite a recent 3.0% drop in share price, Arcturus Therapeutics reported better-than-expected quarterly earnings and revenue, beating analyst estimates.

Y Intercept Hong Kong Ltd bought a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 23,077 shares of the biotechnology company's stock, valued at approximately $244,000. Y Intercept Hong Kong Ltd owned about 0.09% of Arcturus Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in ARCT. Byrne Asset Management LLC lifted its stake in Arcturus Therapeutics by 89.8% in the first quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 1,365 shares during the period. Virtus ETF Advisers LLC raised its position in shares of Arcturus Therapeutics by 38.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock valued at $69,000 after purchasing an additional 1,132 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Arcturus Therapeutics in the 4th quarter valued at approximately $71,000. GAMMA Investing LLC raised its position in shares of Arcturus Therapeutics by 3,482.9% in the 1st quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company's stock valued at $550,000 after purchasing an additional 5,085 shares during the last quarter. Finally, National Bank of Canada FI raised its position in shares of Arcturus Therapeutics by 639.6% in the 4th quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company's stock valued at $94,000 after purchasing an additional 4,784 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ARCT has been the subject of several research analyst reports. Wall Street Zen lowered shares of Arcturus Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, July 5th. HC Wainwright reissued a "buy" rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. Canaccord Genuity Group reduced their price target on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Citigroup reissued a "buy" rating on shares of Arcturus Therapeutics in a research report on Tuesday, May 13th. Finally, Wells Fargo & Company reduced their price target on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Arcturus Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $54.00.

Arcturus Therapeutics Stock Performance

ARCT traded up $0.09 during trading on Friday, reaching $12.30. 361,584 shares of the company's stock were exchanged, compared to its average volume of 436,189. The stock has a market capitalization of $333.58 million, a P/E ratio of -4.86 and a beta of 2.27. Arcturus Therapeutics Holdings Inc. has a 1 year low of $8.04 and a 1 year high of $25.88. The company's fifty day simple moving average is $13.17 and its 200-day simple moving average is $13.53. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.64 and a quick ratio of 5.64.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($1.58) by $1.06. The business had revenue of $29.38 million for the quarter, compared to analysts' expectations of $25.64 million. Arcturus Therapeutics had a negative net margin of 47.47% and a negative return on equity of 27.41%. As a group, research analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.